Related Experiment Videos
Brain-derived neurotrophic factor in experimental autoimmune neuritis
Paul A Felts1, Kenneth J Smith, Norman A Gregson
1Department of Neuroimmunology and the Neuroinflammation Research Group, Guy's, King's and St. Thomas' School of Medicine, King's College London, Guy's Campus, London SE1 1UL, UK. paul.felts@kcl.ac.uk
Journal of Neuroimmunology
|April 18, 2002
Summary
Brain-derived neurotrophic factor (BDNF) did not significantly improve outcomes in a rat model of Guillain-Barré syndrome (GBS). While BDNF showed a potential protective effect on bladder weight, it did not enhance neurological function or survival during the acute disease phase.
Area of Science:
- Neuroscience
- Immunology
- Neurology
Background:
- Guillain-Barré syndrome (GBS) is characterized by long-term disability stemming from axonal and neuronal degeneration.
- Brain-derived neurotrophic factor (BDNF) is known to protect neurons from damage, particularly following motor axon injury.
Purpose of the Study:
- To investigate the therapeutic potential of BDNF in ameliorating the effects of experimental autoimmune neuritis (EAN), an animal model simulating GBS.
- To assess BDNF's ability to prevent neuronal death and improve functional recovery in the context of EAN.
Main Methods:
- Lewis rats were induced with experimental autoimmune neuritis (EAN).
- Animals received daily treatments of Brain-derived neurotrophic factor (BDNF) at a dosage of 10 mg/kg/day.
- Neurological deficits, survival rates, motor function, motor innervation, and urinary bladder weight were evaluated.
Main Results:
- BDNF treatment did not significantly alter the neurological deficit observed in EAN rats.
- Survival, motor function, and motor innervation showed no significant improvement with BDNF administration.
- A significant increase in urinary bladder weight was observed in control EAN animals, but this was not evident in BDNF-treated animals, suggesting a potential protective effect.
Conclusions:
- BDNF may not be an effective therapeutic agent for Guillain-Barré syndrome, particularly during the acute phase of the disease.
- The observed effect on bladder weight suggests a limited, possibly protective, role for BDNF in specific aspects of EAN, warranting further investigation.
- Further research is needed to explore BDNF's efficacy in different phases or variations of GBS.